Navigation Links
Midwest life science stocks sizzle in a tepid first quarter

The overall stock market performance for the first quarter of 2007 was not particularly exciting, although the ensuing three weeks represented a substantial improvement as the Dow Jones Industrials is poised to break through the 13,000 point barrier. So take the results, below, with a grain of salt.

The major life scien......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 04/23/07


Page: 1 2 3 4 5

Related biology technology :

1. Midwest life science stocks kept sizzling in Q2
2. A Midwest passage to India, Part II
3. Midwest offers non-stop flight to North Carolina research park
4. A Midwest life-science odyssey comes full circle
5. Midwest hotter for healthcare investments
6. A Midwest small-cap, life-science surprise package
7. 2006: A mixed blessing for Midwest life science companies
8. Midwest gaining stature in nanotech research
9. Midwest colleges strong contenders for NIH funds
10. Japan on the rebound: Implications for Midwest
11. Investor links East Coast funds to Midwest tech

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Midwest life science stocks sizzle tepid first quarter

(Date:11/20/2009)...ries have an opportunity to take the lead in two s...niversity of Valencia (UV), working together with ...e fabric of the Spanish biotechnology industry. Th...ors have more clout than those in English-speaking...nd plants has been overlooked by the leading count...
(Date:11/20/2009)... Cell Therapeutics, Inc. ...the Ninth Circuit Court of Appeals reversed a U.S.... allowed to pursue all of its claims against The L...ourt for trial. CTI filed a complaint against The...t consultant for CTI,s product TRISENOX, in 2007 s...
(Date:11/19/2009)...ewswire-FirstCall/ -- Omeros Corporation (Nasdaq: ...s for the third quarter ended September 30, 2009. ...ros reported a net loss of $3.9 million, or $1.34 ...on, or $2.54 per share, for the same period in 200...he Company reported a net loss of $15.5 million, o...
(Date:11/19/2009)...WALTHAM, Mass., Nov. 19 Arlington ...d that the leading driver of antibiotic selection ...m activity against gram-positive and gram-negative...an cause nosocomial pneumonia, surveyed European p...ts that provide appropriate coverage against commo...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
... Inc., a subsidiary of,Eisai Corporation of North ...ulti-centered Phase II study of its MORAb-009 mono...aluate MORAb-009, plus the chemotherapy drugs,peme...for patients with,mesothelioma. , The primary ...f MORAb-009,as combination therapy with the curren...
...ll/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: A...new Senior Secured Term Loan and Revolving Credit ...ranger, administrative agent and lender for both t...financing includes a delayed draw secured term loa...olving credit facility with a borrowing base deriv...
... the California Institute for Regenerative Medicin... Stemedica Cell Technologies, Inc. ("Stemedic...;D lab and corporate headquarters. , ...9 -- Leadership of the California Institute for Re... two part visit to Stemedica Cell Technologies, In...
Other Biology Technology:Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4CIRM Completes Briefing Visit to Stemedica Cell Technologies 2CIRM Completes Briefing Visit to Stemedica Cell Technologies 3
(Date:11/20/2009)...ed in the November 2009 issue of the journal GENE... how a family of genes (1-aminocyclopropane-1-carb...r production of ethylene. This gas affects many as...ays the foundation for future genetic manipulation... survive and thrive in difficult terrain, increase...
(Date:11/20/2009)...versity of Oklahoma researchers were sequencing th...me project. Today, the OU Advanced Center for Ge...l effort to sequence the tomato genome with a $7.5...ndation for plant genomics. , "The tomato has t... tomato and crop yields will improve quality of li...
(Date:11/20/2009)...gin of biological molecules like RNA and DNA is ho...rom simple precursors. Now, in a study appearing i...structed one of the earliest evolutionary steps ye...ubunits using nothing but warm water. , Many re...ological molecules present, before DNA and protein...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2NSF awards $7.5M grant to University of Oklahoma for plant genomics 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 1Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 4New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 1New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 2Study demonstrates the anti inflammatory properties of pine bark extract 51856 1Study demonstrates the anti inflammatory properties of pine bark extract 51856 2
...Glynn, a professor at the University of Miamis Ros...as been selected to receive the 2007-2008 Provosts...s extraordinary research and scholarly pursuits, a... continued research support. , This marks the sec... first introduced in 1996, will receive this honor...
...trogen runoff from urban and agriculture land-use ... processes for reducing this pollutant before it e... nationwide team of 31 ecologists, including two f...ems Center. , The findings, published in the Ma... of 72 streams in 8 regions across the U.S. and Pu...
...one of the worlds most endangered speciesa North I...al Zoo Bird House. Keepers had been incubating the...tion by the chicks father, carefully monitoring it...ick starts to break through the shell. The chick r... specially designed brooding box. , The box will...
Other Biology News:UM coral scientist Peter Glynn wins award for scholarly activity 2Increasing nitrogen pollution overwhelms filtering capability of streams 2Rare North Island brown kiwi hatches at the Smithsonian's National Zoo 2
Experion RNA StdSens Chips, 10 from Bio-Rad
MiniMACS Separation Unit from Miltenyi Biotec
Experion RNA HighSens Chips, 10 from Bio-Rad
...activated with carbonyl diimidazole chemistry that...e PS10 array contains the same binding chemistry a...hobic barrier coating. These arrays are 8 spot chi...ith one column of a standard 96-well microplate (9...
Biology Products: